PCSA · Processa Pharmaceuticals, Inc. · Analyst Estimates
$1.85
-0.14 (-7.04%)
At close · Sep 10
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.56M
Shares
2.79M
Analyst Estimates
Compare analyst forecasts for Processa Pharmaceuticals, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Only independently verified consensus published through the company's investor-relations sources is available.
Consensus not yet available
Only independently verified consensus published through the company's investor-relations sources is available.
Key facts
CIK
1533743
CUSIP
74275C403
13F (30d)
11 filings
11 filers
Visit website
Investor relations